Bionanao Genomics Inc (BNGO)

[wannabeeriche]

OGM Officially Insured, Clinically Validated


Bionano Genomics’ OGM is rapidly becoming integral to genomic diagnostics.

The U.S. Centers for Medicare & Medicaid Services (CMS) assigned a unique payment indicator to CPT 81195 in its 2025 Clinical Laboratory Fee Schedule, setting a national reimbursement rate that private payers often mirror.

Payers like Blue Cross Blue Shield and UnitedHealthcare have convened molecular pathology advisory panels in 2024 to develop internal coverage policies for OGM, citing its inclusion in CPT and CAP/AMP guidelines as the evidentiary foundation. Looking ahead, emerging CPT II codes for reporting OGM quality metrics (e.g., molecule N50, label density) are under review, which will further standardize how labs document and insurers recognize OGM performance.

NHS England’s Genomic Test Directory (April 2025) now lists OGM as an approved test under its UK-wide Genomic Medicine Service for both oncology (acute leukemias) and constitutional SV screening. Each Trust receives a defined tariff to cover OGM reagents, instrument time, and bioinformatics.

APS Medical Billing’s 2025 CPT update guide highlights CPT 81195 and assigns it to revenue codes 0300, 0309, 0310, and 0319, ensuring pathology departments know exactly how to report and track OGM claims.

BNGO - Encourage clinical labs to invest in OGM platforms and staff training.